AbCellera Biologics Inc.

NASDAQ:ABCL

2.74 (USD) • At close September 19, 2024
Overview | Financials

Numbers are in millions (except for per share data and ratios) USD.

2024 Q22024 Q12023 Q42023 Q32023 Q22023 Q12022 Q42022 Q32022 Q22022 Q12021 Q42021 Q32021 Q22021 Q12020 Q42020 Q32020 Q22020 Q12019 Q42019 Q32019 Q22019 Q1
Revenue 7.3239.9549.1796.59910.05612.19221.545101.38345.917316.581139.3315.50827.643202.741207.9089.36211.2284.6573.2023.4512.4792.479
Cost of Revenue 38.0376.7669.1097.4097.25652.6471.55415.0355.2144.63721.89417.453.6120.0135.7797.4959.1444.1183.3092.7822.0112.011
Gross Profit -30.7143.1880.07-0.812.8-40.45519.99186.34840.707271.944117.437-11.94224.033182.731172.1291.8672.0840.539-0.1060.6690.4680.468
Gross Profit Ratio -4.1940.320.008-0.1230.278-3.3180.9280.8520.8870.8590.843-2.1680.8690.9010.8280.1990.1860.116-0.0330.1940.1890.189
Reseach & Development Expenses 40.92739.28748.62237.91736.47352.64728.24526.58226.68526.36617.20917.4515.04612.3528.6367.4959.1444.1183.3092.7822.0112.011
General & Administrative Expenses 20.19217.35215.97414.36915.52115.13413.01513.79214.41214.26812.8911.27111.2036.4225.7942.9681.4981.650.9750.7030.5350.535
Selling & Marketing Expenses 3.1363.3653.13.4683.8413.7712.6913.0893.122.371.8271.2171.2952.5782.2320.6260.5470.4370.4710.2910.250.25
SG&A 21.81318.79519.07417.83719.36218.90515.70616.88117.53216.63814.71712.48812.49898.0263.5942.0452.0871.4460.9940.7860.786
Other Expenses 32.156-1.5293.1062.046-1.972.1412.14333.351-1.204-1.354-1.2560.3140.2655.226-2.262-0.293-1.001-0.111000
Operating Expenses 62.7458.08271.85658.66156.86973.69256.09446.46347.56841.830.57229.22426.4221.50921.8889.7934.2325.7494.6430.6260.7660.766
Operating Income -93.454-54.894-66.053-54.89-51.389-61.5-36.10337.735-6.861224.9581.553-28.096-7.033158.074160.774-1.768-0.854-2.122-1.976-0.716-0.713-0.713
Operating Income Ratio -12.762-5.515-7.196-8.318-5.11-5.044-1.6760.372-0.1490.7110.585-5.101-0.2540.780.773-0.189-0.076-0.456-0.617-0.207-0.287-0.287
Total Other Income Expenses Net 45.26712.1473.1062.046-1.9713.3524.6918.852-0.0255.859-0.26-1.2560.3140.265-1.446-2.262-0.293-1.001-0.1620.7520.410.41
Income Before Tax -48.187-42.747-48.602-39.276-38.004-48.148-31.41246.587-6.886230.80984.71-24.972-2.073161.487155.915-2.6936.703-2.093-1.6410.036-0.303-0.303
Income Before Tax Ratio -6.58-4.294-5.295-5.952-3.779-3.949-1.4580.46-0.150.7290.608-4.534-0.0750.7970.75-0.2880.597-0.449-0.5120.01-0.122-0.122
Income Tax Expense -11.257-2.137-1.452-10.666-7.476-8.038-1.51919.963-0.10162.23624.762-3.5920.2544.2660.0390000.082000
Net Income -36.93-40.61-47.15-28.61-30.528-40.11-29.89326.624-6.785168.57359.948-21.38-2.323117.221117-2.6936.703-2.093-1.6410.036-0.303-0.303
Net Income Ratio -5.043-4.08-5.137-4.336-3.036-3.29-1.3870.263-0.1480.5320.43-3.882-0.0840.5780.563-0.2880.597-0.449-0.5120.01-0.122-0.122
EPS -0.13-0.14-0.16-0.099-0.11-0.14-0.10.084-0.0240.540.21-0.08-0.0090.430.43-0.010.031-0.01-0.0080-0.002-0.002
EPS Diluted -0.13-0.14-0.16-0.099-0.11-0.14-0.10.084-0.0240.540.21-0.077-0.0090.370.37-0.010.028-0.009-0.0070-0.002-0.002
EBITDA -55.417-48.128-53.568-44.653-39.557-54.38-4.66446.613-0.82235.11794.203-19.511.828165.188162.3040.5068.076-0.446-0.899-0.326-0.318-0.318
EBITDA Ratio -7.568-4.835-5.836-6.767-3.934-4.46-0.2160.46-0.0180.7430.676-3.5420.0660.8150.7810.0540.719-0.096-0.281-0.094-0.128-0.128